<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313725</url>
  </required_header>
  <id_info>
    <org_study_id>DOC-55</org_study_id>
    <nct_id>NCT04313725</nct_id>
  </id_info>
  <brief_title>Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease</brief_title>
  <official_title>An Evaluation of Tangible Boost Replenishing System for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Versus Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tangible Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Sight</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tangible Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to determine if the Tangible Boost system adequately replenishes&#xD;
      the Hydra-PEG coating on the surface of a rigid contact lens.&#xD;
&#xD;
      Hydra-PEG is a coating for soft and rigid contact lens, primarily composed of polyethylene&#xD;
      glycol-based hydrogel, which is covalently bound to the surface of a contact lens. The&#xD;
      Hydra-PEG coating is intended to improve wettability and comfort with contact lenses and is&#xD;
      currently FDA approved on a number of contact lenses. For patients with Stevens Johnson&#xD;
      Syndrome (SJS) (SS), or Graft versus Host disease (GVHD), diminished efficacy of the&#xD;
      Hydra-PEG coating can lead to significant decline in satisfaction with the lenses over time.&#xD;
      This is a prospective study to evaluate the efficacy of Tangible Boost, a monthly&#xD;
      conditioning solution, to replenish the Hydra-PEG coating on rigid gas permeable contact&#xD;
      lenses for patients with SJS, GVHD, and SS. Outcomes from this patient population will be&#xD;
      compared to patients with dry eye disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Test and placebo treatment kits will be randomized by the sponsor prior to sending to clinical site.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Snellan visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>6 months</time_frame>
    <description>Snellan visual acuity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contact Lens Comfort</measure>
    <time_frame>3 months</time_frame>
    <description>OSDI plus additional specific questions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contact Lens Comfort</measure>
    <time_frame>6 months</time_frame>
    <description>OSDI plus additional specific questions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Staining</measure>
    <time_frame>3 months</time_frame>
    <description>Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Staining</measure>
    <time_frame>6 months</time_frame>
    <description>Sodium fluorescein staining will be used to evaluate ocular surface damage indicated by cell damage or death. Corneal staining will be scored using the Oxford grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear break up time</measure>
    <time_frame>3 months</time_frame>
    <description>Seconds required for tear film to begin to break up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear break up time</measure>
    <time_frame>6 months</time_frame>
    <description>Seconds required for tear film to begin to break up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contact lens fit characteristics</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in apical clearance, limbal clearance, scleral landing evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Stevens-Johnson Syndrome</condition>
  <condition>Graft Versus Host Disease in Eye</condition>
  <condition>Sjogren's Syndrome</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use the Tangible Boost treatment on their lenses monthly throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will use a Placebo treatment (saline) on their lenses monthly throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tangible Boost</intervention_name>
    <description>Patients will perform a monthly Tangible Boost treatment on their Hydra-PEG treated contact lenses.</description>
    <arm_group_label>Boost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will perform a monthly placebo (saline) treatment on their Hydra-PEG treated contact lenses.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written Informed Consent has been obtained prior to any study-related procedures&#xD;
             taking place&#xD;
&#xD;
          -  Written documentation has been obtained in accordance with the relevant county and&#xD;
             local privacy requirements, where applicable&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  18 years of age and older prior to the initial visit&#xD;
&#xD;
          -  Is a new or established wearer of PROSE lenses with optimized lens fit prior to&#xD;
             enrollment in the study&#xD;
&#xD;
          -  Has been diagnosed with Dry Eye Syndrome, SJS, SS, or GVHD&#xD;
&#xD;
          -  In the opinion of the investigator, the subject has the ability to follow study&#xD;
             instructions&#xD;
&#xD;
          -  In the opinion of the investigator, the subject has the ability to complete all study&#xD;
             procedures and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  aphakic (i.e., missing their natural lens inside the eye)&#xD;
&#xD;
          -  Is currently participating in any other type of eye-related clinical or research study&#xD;
&#xD;
          -  Is pregnant or nursing as reported by the subject&#xD;
&#xD;
          -  Has a condition or is in a situation which, in the investigator's opinion, may put the&#xD;
             subject at significant risk, may confound study outcomes, or may significantly&#xD;
             interfere with the subject's participation in the study.&#xD;
&#xD;
          -  Has a known and self-reported allergy to the following substances: polyethylene&#xD;
             glycol, polyvinyl alcohol, triethanolamine, polyquaternium-1, or edetate disodium,&#xD;
             which are components of the Tangible Boost and Hydra-PEG systems or care regimen.&#xD;
&#xD;
          -  Has had previous ocular surgery within the past 12 weeks&#xD;
&#xD;
          -  Adults unable to consent (including adults unable to read and understand English)&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Employees of BostonSight&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Carrasquillo, OD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Sight</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly Mabry, Ph.D.</last_name>
    <phone>+1 (650) 241-1045</phone>
    <phone_ext>108</phone_ext>
    <email>kelly@tangiblescience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estelle Crowley</last_name>
    <phone>781-726-7506</phone>
    <email>ecrowley@bostonsight.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Sight</name>
      <address>
        <city>Needham</city>
        <state>Massachusetts</state>
        <zip>02494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Crowley</last_name>
      <phone>781-726-7506</phone>
      <email>ecrowley@bostonsight.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Carrasquillo, OD, PhD</last_name>
      <phone>781-726-7518</phone>
      <email>kcarrasquillo@bostonsight.org</email>
    </contact_backup>
    <investigator>
      <last_name>Karen Carrasquillo, OD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lens care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

